Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

14 Countries

Phase II

Phase II: 2

Oversight events:

6 temporary halts across 1 trial

View oversight register →

Sponsors using this IMP

Eli Lilly & Co. 2

All trials

2 total

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Phase II 14 countries Eli Lilly & Co.
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2023-505608-43-00 Phase II 3 countries Eli Lilly & Co.

Showing 1–2 of 2 trials

← All drugs A–Z